Sofwave Medical Ltd. SOFW

NMPA approval supported by a 200-subject, randomized, controlled study in China demonstrating statistically significant improvement in mid-to-lower facial wrinkles and a favorable safety profile China represents a growing medical aesthetic market, with the market for non-invasive/minimally invasive procedures valued at RMB 146.0 billion (approximately US$20.6 billion) in 20231 SAN CLEMENTE, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd. (TASE: SOFW), a global regenerative aesthe

SAN CLEMENTE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference on September 8-10, 2026. About Sofwave MedicalSofwave Medical Ltd. (TASE: SOFW) is a global

A prospective randomized controlled trial of an aesthetic EMS platform to assess objective functional performance reports improvements across four standardized testsSAN CLEMENTE, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd. (TASE: SOFW), a global regenerative aesthetics company advancing non-invasive technologies for skin and body, today announced the publication of data from a new randomized controlled clinical study of the Company’s proprietary PlyoPulse™ technology, titled “

Global milestone reflects sustained physician utilization, patient adoption and the expanding reach of Sofwave’s SUPERB™ technologySAN CLEMENTE, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd. (TASE: SOFW), a global regenerative aesthetics company advancing non-invasive technologies for skin and body, today announced that it has surpassed one million Sofwave® treatments worldwide. The milestone treatment was performed in South Korea, one of the world’s most sophisticated and compe

Second quarter revenue of $30M, +43% year-over-year growth; IFRS gross margin of 76.5%Second quarter usage fee revenue of $13.9M, 52.2% year-over-year growthFirst half revenue of $54.4M, +44% year-over-year growth; IFRS gross margin of 75.8%Second quarter IFRS and non-IFRS net income of $2.5M and $3.0M (or $3.8M exc. one-time expenses), versus IFRS and non-IFRS net income of $1.5M and $2.2M in the prior year periodGenerated $3.6M in cash in the second quarterApproximately 3,100 Sofwave systems s

SAN CLEMENTE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference on August 10 – 11, 2026. About Sofwave MedicalSofwave Medical Ltd. has implemented an innovative

First quarter revenue of $24.4M, +46% year-over-year growth; IFRS gross margin of 75.0%First quarter usage fee revenue of $11.0M, +56% year-over-year growth IFRS and non-IFRS net income of $1.3M and $1.7M versus IFRS and non-IFRS net losses of $1.1M and $0.4M in the prior year ago periodApproximately 2,900 Sofwave systems sold to date and more than 865,000 Sofwave treatments administered since commercialization SAN CLEMENTE, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOF

Record quarterly revenue in fourth quarter of $28.9M, +58% year-over-year growth; IFRS gross margin of 75.6% Fourth quarter pulse recurring revenue of $13.2M, +83% year-over-year growthFull fiscal year 2025 revenue of $87.6M, +47% year-over-year growth; IFRS gross margin of 75.3% Company achieves net profitability with full fiscal year 2025 IFRS and non-IFRS net income of $5.5M and $7.8M, respectively, versus a net loss of $4.5M and $2.1M, respectively, in the same period last year Approximately